

**NYSTATIN- nystatin suspension**  
**Preferred Pharmaceuticals, Inc.**



-----  
**NYSTATIN ORAL**  
**SUSPENSION, USP**

**(100,000 units per mL)**

**Rx only**

**DESCRIPTION**

Nystatin is an antimycotic polyene antibiotic obtained from *Streptomyces noursei*.  
Structural formula:



Nystatin Oral Suspension, for oral administration, contains 100,000 USP Nystatin Units per mL. Inactive ingredients: alcohol ( $\leq 1\%$  v/v), artificial wild cherry flavor, banana flavor, D&C yellow #10, FD&C red #40, glycerin, USP, magnesium aluminum silicate, methylparaben, NF, potassium phosphate dibasic, USP, propylene glycol, USP, propylparaben, NF, purified water, USP and sucrose 33.5%. May also contain citric acid, USP for pH adjustment.

**CLINICAL PHARMACOLOGY**

**Pharmacokinetics**

Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.

**Microbiology**

Nystatin is both fungistatic and fungicidal *in vitro* against a wide variety of yeasts and yeast-like fungi. *Candida albicans* demonstrates no significant resistance to nystatin *in vitro* on repeated subculture in increasing levels of nystatin; other *Candida* species become quite resistant. Generally, resistance does not develop *in vivo*. Nystatin acts by binding to sterols in the cell membrane of susceptible *Candida* species with a resultant

change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

## **INDICATIONS AND USAGE**

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

## **CONTRAINDICATIONS**

The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.

## **PRECAUTIONS**

### **General**

This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.

### **Carcinogenesis, Mutagenesis, Impairment of Fertility**

No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.

### **Pregnancy**

#### **Teratogenic Effects Category C**

Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.

### **Nursing Mothers**

It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

### **Pediatric Use**

See **DOSAGE AND ADMINISTRATION**.

## **ADVERSE REACTIONS**

Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See **PRECAUTIONS: General**).

*Gastrointestinal:* Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.

*Dermatologic:* Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.

*Other:* Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported.

## **OVERDOSAGE**

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (see **CLINICAL PHARMACOLOGY, Pharmacokinetics**).

## **DOSAGE AND ADMINISTRATION**

**INFANTS:** 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).

**NOTE:** Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.

**CHILDREN AND ADULTS:** 4-6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.

Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of *Candida albicans*.

## **HOW SUPPLIED**

Nystatin Oral Suspension, USP, 100,000 USP Nystatin Units per mL, is available as a fruit flavored, light creamy yellow, ready-to-use suspension.

60 mL bottles was a calibrated dropper and

1 Pint (473 mL) bottles (68788-6792-6)

## **Storage**

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Avoid freezing

## **Rx Only**

Product No.: 8537

## **Manufactured For:**

**Wockhardt USA, LLC**

**Parsippany, NJ 07054**

## **Manufactured By:**

**Morton Grove Pharmaceuticals, Inc.**

Morton Grove, IL 60053

A50-8537-16

REV. 07-18

Relabeled By: Preferred Pharmaceuticals Inc.

**PRINCIPAL DISPLAY PANEL Bottle Carton**

**MGP**

NDC 68788-6792-6

**NYSTATIN ORAL  
SUSPENSION, USP  
(100,000 units  
per mL)**

**Fruit Flavored**


**SHAKE WELL BEFORE USING**

**DO NOT USE IF INNER FOIL SEAL PRINTED "SEALED FOR YOUR PROTECTION"  
IS BROKEN OR MISSING**

**Rx Only**


**NET: 1 Pint (473 mL)**

Relabeled By: Preferred Pharmaceuticals Inc.

<p><b>Nystatin Oral Suspension, USP</b></p> <p>Generic for: Mycostatin</p> <p>Each mL contains: 100,00 units Nystatin, USP</p> <p><b>Pkg Size:</b> Exp Date: Lot#: Batch#: Ins:</p> <p>Mfg: Morton Grove Pharmaceuticals; Morton Grove, IL</p> <p>Prod#: Warning</p> <p><small>Fruit Flavored. Packaged with Calibrated Dropper, Safety Sealed Bottle. Keep this and all medication out of reach of children. In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately. Store at 20° - 25°C (68° - 77°F). See USP Controlled Room Temperature. Shake well before using. Avoid freezing. Before dispensing, replace cap with safety cap dropper. See package for dosage. Rx Only.</small></p>		<p>CAUTION: Federal law PROHIBITS transfer of this drug to any person other than the patient for whom it was prescribed</p>	<p>Nystatin Oral Suspension, USP Qty: Ins: Lot#: Bat#:</p>	<p>Log</p>		
					<p>Prod# (NDC):</p>	<p>Chart</p>
					<p>Nystatin Oral Suspension, USP Qty: Ins: Lot#: Bat#: Prod# (NDC):</p>	
						<p>Nystatin Oral Suspension, USP Qty: Ins: Lot#: Bat#: Prod# (NDC):</p>

**Directions English**

**Take as Directed**



**Instrucciones Espanol:**

**Tomelo como se indica**

**Nystatin Label**

<b>NYSTATIN</b>
nystatin suspension
<b>Product Information</b>

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:68788-6792(NDC:60432-537)	
<b>Route of Administration</b>	ORAL			
<b>Active Ingredient/Active Moiety</b>				
<b>Ingredient Name</b>		<b>Basis of Strength</b>	<b>Strength</b>	
Nystatin (UNII: BDF1O1C72E) (Nystatin - UNII:BDF1O1C72E)		Nystatin	100000 [USP'U] in 1 mL	
<b>Inactive Ingredients</b>				
<b>Ingredient Name</b>			<b>Strength</b>	
water (UNII: 059QF0KO0R)				
magnesium aluminum silicate (UNII: 6M3P64V0NC)				
propylene glycol (UNII: 6DC9Q167V3)				
glycerin (UNII: PDC6A3C0OX)				
sucrose (UNII: C151H8M554)				
DIBASIC POTASSIUM PHOSPHATE (UNII: CI71S98N1Z)				
alcohol (UNII: 3K9958V90M)				
methylparaben (UNII: A2I8C7HI9T)				
propylparaben (UNII: Z8IX2SC1OH)				
D&C yellow no. 10 (UNII: 35SW5USQ3G)				
FD&C red no. 40 (UNII: WZB9127XOA)				
<b>Product Characteristics</b>				
<b>Color</b>	YELLOW (Light creamy yellow)		<b>Score</b>	
<b>Shape</b>			<b>Size</b>	
<b>Flavor</b>	FRUIT		<b>Imprint Code</b>	
<b>Contains</b>				
<b>Packaging</b>				
<b>#</b>	<b>Item Code</b>	<b>Package Description</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>
1	NDC:68788-6792-6	60 mL in 1 BOTTLE, PLASTIC; Type 0: Not a Combination Product	11/02/2016	
<b>Marketing Information</b>				
<b>Marketing Category</b>	<b>Application Number or Monograph Citation</b>	<b>Marketing Start Date</b>	<b>Marketing End Date</b>	
ANDA	ANDA062512	11/02/2016		

**Labeler** - Preferred Pharmaceuticals, Inc. (791119022)

**Registrant** - Preferred Pharmaceuticals, Inc. (791119022)

## Establishment

Name	Address	ID/FEI	Business Operations
Preferred Pharmaceuticals, Inc.		791119022	RELABEL(68788-6792)

Revised: 8/2023

Preferred Pharmaceuticals, Inc.